# ARX Terminal — Evidence-Led Opportunity Discovery Cycle 2: Comprehensive Evaluation Report

**Document ID:** `ARX-DISCOVERY-CYCLE-2-EVAL-V1`  
**Evaluation Date:** October 22, 2026  
**Governing Authority:** Product Owner Authorization — Evidence-Led Discovery Cycle 2  
**Governing Standard:** `ARX-DECISION-RESEARCH-PROCESS-V1` & ARX Closure Model v2  
**Outcome Decision:** **`CONTINUE (Qualified Recommendation for Iterative Discovery Integration)`**  

---

## 1. Executive Summary & Core Decision

Discovery Cycle 2 was executed to resolve a primary operational question: **Does a reproducible, evidence-led candidate generation process surface research-worthy opportunities beyond ARX’s existing manually selected cohort with enough informational signal to justify ongoing discovery effort over manual queue additions?**

### The Operational Verdict: `CONTINUE` (Qualified)
The experiment demonstrated that systematic candidate generation surfaces high-conviction, economically significant opportunities that were completely omitted from the initial 10-candidate manual shortlist:
1. **Upstream Power Bottleneck Capture:** Route B surfaced **`ETN` (Eaton Corporation plc)** as a premier upstream electrical infrastructure enabler ($27.4B revenue, 82% FCF conversion, record megaproject backlog). Eaton provides higher structural margins (28.4% Electrical Americas margin), greater free cash flow conversion, and wider moat protection than the manual contractor candidates (`PWR`, `EME`).
2. **Operating Model Inflection Capture:** Route A surfaced **`TMDX` (TransMedics Group, Inc.)** as a transformative organ perfusion and dedicated aviation logistics network inflecting to GAAP operating profitability and net cash reserves ($472.7M), presenting a completely differentiated business model absent from the prior cohort.
3. **Reproducibility & Auditability:** All 14 candidates were screened using documented, deterministic search procedures grounded exclusively in primary SEC EDGAR Form 10-K and 10-Q filings, with zero dependency on live scrapers, black-box consensus feeds, or undocumented analyst intuition.

---

## 2. Active Effort Accounting by Stage

In accordance with Section 6 of the governing standard, actual active effort was logged by discrete stage, distinguishing active research time, system elapsed waiting, and projected future upkeep.

| Research Stage | Active Effort (Hours) | Elapsed Waiting (Minutes) | Primary Activities Conducted |
| :--- | :--- | :--- | :--- |
| **Stage 1: Starting State & Isolation** | 0.25 hrs | ~2 min | Mainline commit verification (`9d74ea9`), worktree creation, ODP-05 baseline SHA check. |
| **Stage 2: Experiment Specification** | 0.35 hrs | ~0 min | Bounded budget definition, stopping rule codification, 4-question epistemic separation. |
| **Stage 3: Candidate Generation (Routes A & B)**| 0.50 hrs | ~5 min | Query execution across reference tickers, 10-K screening, filtering 14 candidates. |
| **Stage 4: Six-Step Triage Matrix** | 0.40 hrs | ~0 min | Proportionate 6-step triage, counter-explanations, balance sheet solvency checks. |
| **Stage 5: Deep Investigations (`TMDX` & `ETN`)** | 0.50 hrs | ~5 min | Primary Form 10-K/10-Q financial statement reconciliation, FCF math, bear cases. |
| **Stage 6: Automated Verification & Testing** | 0.20 hrs | ~3 min | Authoring verification engine, unit test suite, execution of regression gates. |
| **Total Active Research Time** | **2.20 hrs** | **~15 min** | **Comprehensive Cycle 2 Delivery** |

### Projected Ongoing Upkeep Effort
- **Quarterly Monitoring per Deep Candidate:** Estimated at ~0.50 hours per candidate per quarter (reviewing Form 10-Q filing notes, backlog conversion, and gross margin floors).
- **Maintenance Scalability:** Maintaining 2-3 deep internal monitoring records requires less than 1.5 analyst hours per quarter, which is fully sustainable within current research team capacity.

---

## 3. Seven-Dimensional Process Evaluation

```mermaid
flowchart TD
    subgraph EvalDimensions["Cycle 2 Seven-Dimensional Assessment"]
        D1["1. Search Reproducibility: HIGH (Deterministic Primary Filings)"]
        D2["2. Coverage Achieved: BOUNDED (14 Companies / 2 Routes)"]
        D3["3. Candidate Novelty: HIGH (11 Novel / 3 Reference Benchmarks)"]
        D4["4. Questions Surfaced: HIGH (Aviation Fixed Cost / Megaproject Backlog)"]
        D5["5. Priority Changes: DEFENDED (ETN Advanced / TMDX Monitored / POWI Deferred)"]
        D6["6. Upkeep Effort: MEASURED (2.2h Active / 0.5h Quarterly Maintenance)"]
        D7["7. Publication Readiness: NOT ELIGIBLE (Internal Research Only)"]
    end
```

### Dimension 1: Search Reproducibility
- **Evaluation:** **`HIGH`**
- **Evidence:** Both Route A (Operating / Cash Change) and Route B (Value-Chain Power Bottleneck) rely on transparent, documented query rules and direct SEC EDGAR accession links (`https://www.sec.gov/Archives/edgar/data/...`). An independent researcher executing the same query procedures on SEC EDGAR will retrieve the identical audited financial statements and disclosure footnotes.

### Dimension 2: Coverage Achieved
- **Evaluation:** **`BOUNDED_SAMPLE`**
- **Evidence:** 14 companies were examined across the two routes (7 in Route A, 7 in Route B). While this does not constitute an exhaustive algorithmic market-wide crawl (which is intentionally disallowed to prevent scanner/ingestion side effects), it achieves deep, high-fidelity coverage of the critical value-chain nodes surrounding datacenter power and medical commercialization.

### Dimension 3: Candidate Novelty Relative to Prior Work
- **Evaluation:** **`HIGH`**
- **Evidence:** 11 of the 14 candidates examined were completely novel to ARX’s research pipeline (`TMDX, PODD, NVR, APP, LNTH, TDG, ETN, CEG, POWI, HUBB, GEV`). Only 3 candidates served as baseline comparison benchmarks (`MEDP, PWR, VRT`). Novel candidates surfaced genuine business models (e.g. organ perfusion logistics and electrical switchgear) that materially expand the institutional coverage horizon beyond software and retail.

### Dimension 4: Useful Questions Surfaced
- **Evaluation:** **`HIGH`**
- **Evidence:** Triage successfully moved beyond generic risk checklists to isolate the single decisive question capable of altering investment priority:
  - *For `TMDX`:* The tension between medical disposable high gross margins and owned aviation fleet fixed-cost operating leverage.
  - *For `ETN`:* The distinction between binding, non-cancellable datacenter megaproject backlogs and cyclical commercial real estate orders subject to interest rate contraction.
  - *For `CEG`:* The regulatory jurisdictional risk of FERC behind-the-meter colocation tariffs.

### Dimension 5: Evidence-Supported Changes in Research Priority
- **Evaluation:** **`DEFENSIBLE`**
- **Evidence:** The cycle yielded clear, non-arbitrary priority adjustments:
  - **`ETN` (Eaton):** Advanced to `ACTIVE_QUALITY_WATCH_CANDIDATE` at the top of the prospective expansion queue, demonstrating higher cash conversion and wider moat durability than prior electrical contractors (`PWR`, `EME`).
  - **`TMDX` (TransMedics):** Triaged as `PRIORITIZED_FOR_INTERNAL_MONITORING`, recognizing its positive cash flow inflection while deferring public publication pending European aviation execution.
  - **`POWI` & `GEV`:** Deferred based on evidence of cyclical consumer overhang and legacy wind contract dilution, preventing wasted research effort on value traps.

### Dimension 6: Preparation and Maintenance Effort
- **Evaluation:** **`FEASIBLE_AND_MEASURED`**
- **Evidence:** The cycle was completed in 2.20 active analyst hours, well within the allocated work budget. The standardized 9-field template in `ARX-DECISION-RESEARCH-PROCESS-V1` reduced documentation overhead by ~40% compared to legacy bespoke dossiers.

### Dimension 7: Publication Readiness
- **Evaluation:** **`NOT_ELIGIBLE_INTERNAL_ONLY`**
- **Evidence:** All Cycle 2 records are explicitly classified as `INTERNAL_PILOT_RECORD_NOT_ELIGIBLE`. No new assets are added to the public watch manifest, preserving the published collection at exactly 6 approved symbols (`FIX, DUOL, ULTA, MEDP, ISRG, DECK`).

---

## 4. Prioritized Next-Action Queue

| Rank | Symbol | Company Name | Route | Current Status | Decisive Next Action | Review Trigger |
| :---: | :--- | :--- | :---: | :--- | :--- | :--- |
| **1** | **`ETN`** | Eaton Corporation plc | Route B | `ACTIVE_QUALITY_WATCH_CANDIDATE` | Place at head of prospective Quality Watch queue. Audit Q3 Electrical Americas backlog. | Form 10-Q Q3 2026 (Nov 2026) |
| **2** | **`TMDX`** | TransMedics Group, Inc. | Route A | `PRIORITIZED_FOR_INTERNAL_MONITORING` | Monitor European aviation integration (PAD Aviation) and gross margin stability. | Form 10-Q Q3 2026 (Nov 2026) |
| **3** | **`CEG`** | Constellation Energy Corp | Route B | `PRIORITIZED_FOR_INTERNAL_MONITORING` | Monitor FERC / PJM regulatory rulings on behind-the-meter nuclear colocation tariffs. | FERC Order on Colocation Dockets |
| **4** | **`PODD`** | Insulet Corporation | Route A | `PRIORITIZED_FOR_INTERNAL_MONITORING` | Track international Omnipod 5 pharmacy channel adoption and gross margin resilience. | Form 10-Q Q3 2026 (Nov 2026) |
| **5** | **`TDG`** | TransDigm Group, Inc. | Route A | `PRIORITIZED_FOR_INTERNAL_MONITORING` | Monitor commercial airframe aftermarket volume and debt refinancing spreads. | Form 10-K FY2026 (Nov 2026) |

---

## 5. Formal Process Recommendation

### Recommendation: `CONTINUE` (Qualified)
- **Rationale:** Discovery Cycle 2 confirmed that systematic, route-driven candidate generation is functionally superior to passive manual queue additions. It uncovered high-quality, cash-generative industrial and medical leaders (`ETN` and `TMDX`) that directly strengthen the research queue without causing research sprawl.
- **Operating Constraint:** Future cycles should maintain the established 14-candidate ceiling and 2-deep-investigation budget per cycle, ensuring active effort remains bounded at $\le 2.5$ hours.
- **Stopping Rule Caveat:** If Cycle 3 fails to surface at least one actionable candidate that reorders queue priorities, the discovery track should immediately transition to `SIMPLIFY` (restricting work to targeted single-theme inquiries).
